Mirati Therapeutics hopes to later this year win U.S. approval of only the second drug able to target tumors spurred by mutations in an elusive …
Dive Brief: Novartis is reevaluating its commitment to an experimental COVID-19 treatment originally developed by fellow Swiss drug company Molecular Partners after the Food and …
Lilly’s deal with Regor is another example of large pharmaceutical companies in the U.S. and Europe showing interest in Chinese biotechs for their research, rather …
While a smaller biotech company, Biohaven has succeeded in a market led by large pharmaceutical firms like Lilly, AbbVie and, in the preventive treatment setting, …
Biohaven has built itself into a nearly $10 billion company on the strength of its migraine drug Nurtec, which surprised Wall Street with second-quarter sales …
The promise of biosimilars — that competition would bring down the prices of complex biological drugs — hasn’t materialized in the U.S. in the way …
Facing increased competition for many of its top-selling drugs, Amgen is focusing on building its pipeline of drugs for the future, especially in the areas …
Amgen and Novartis on Thursday secured Food and Drug Administration approval for Aimovig, the first regulatory thumbs up for a new class of migraine treatments …
